The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2011, Pages 377-385

  Müller, Holger Christian ^a   Hocke, Andreas Christian ^a   Hellwig, Katharina ^a   Gutbier, Birgitt ^a   Peters, Harm ^a   Schönrock, Stefanie Maria ^a   Tschernig, Thomas ^b   Schmiedl, Andreas ^c   Hippenstiel, Stefan ^a   N'Guessan, Philippe Dje ^a   Rosseau, Simone ^a   Suttorp, Norbert ^a   Witzenrath, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute lung injury; Apoptosis; FTY720; Vascular permeability; Ventilator induced lung injury

Indexed keywords

FINGOLIMOD; OXYGEN; PROCASPASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG MEGADOSE; ELECTRIC RESISTANCE; ELECTRON MICROSCOPY; ENDOTHELIUM; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MORPHOLOGY; MOUSE; NICK END LABELING; NONHUMAN; OXYGENATION; PERMEABILITY; PRIORITY JOURNAL; TIDAL VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; VENTILATOR INDUCED LUNG INJURY;

ANIMALS; APOPTOSIS; CAPILLARY PERMEABILITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED C57BL; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; VENTILATOR-INDUCED LUNG INJURY;

EID: 79956125830     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.01.017     Document Type: Article

References (45)

1. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105.
2. Habicht A., Clarkson M.R., Yang J., Henderson J., Brinkmann V., Fernandes S., et al. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol 2006, 176:36-42.
3. Budde K., Schmouder R.L., Brunkhorst R., Nashan B., Lucker P.W., Mayer T., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002, 13:1073-1083.
4. Salvadori M., Budde K., Charpentier B., Klempnauer J., Nashan B., Pallardo L.M., et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006, 6:2912-2921.
5. Tedesco-Silva H., Szakaly P., Shoker A., Sommerer C., Yoshimura N., Schena F.P., et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007, 84:885-892.
6. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
7. Comi G., O'Connor P., Montalban X., Antel J., Radue E.W., Karlsson G., et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010, 16:197-207.
8. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140.
9. O'Connor P., Comi G., Montalban X., Antel J., Radue E.W., de Vera A., et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009, 72:73-79.
10. Wang L., Dudek S.M. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 2009, 77:39-45.
11. Garcia J.G., Liu F., Verin A.D., Birukova A., Dechert M.A., Gerthoffer W.T., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001, 108:689-701.
12. Dudek S.M., Jacobson J.R., Chiang E.T., Birukov K.G., Wang P., Zhan X., et al. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004, 279:24692-24700.
13. Singleton P.A., Dudek S.M., Chiang E.T., Garcia J.G. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. FASEB J 2005, 19:1646-1656.
14. Peng X., Hassoun P.M., Sammani S., McVerry B.J., Burne M.J., Rabb H., et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004, 169:1245-1251.
15. McVerry B.J., Peng X., Hassoun P.M., Sammani S., Simon B.A., Garcia J.G. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004, 170:987-993.
16. Liu H.B., Cui N.Q., Wang Q., Li D.H., Xue X.P. Sphingosine-1-phosphate and its analogue FTY720 diminish acute pulmonary injury in rats with acute necrotizing pancreatitis. Pancreas 2008, 36:e10-e15.
17. Okazaki M., Kreisel F., Richardson S.B., Kreisel D., Krupnick A.S., Patterson G.A., et al. Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant 2007, 7:751-758.
18. Wadgaonkar R., Patel V., Grinkina N., Romano C., Liu J., Zhao Y., et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol 2009, 296:L603-L613.
19. Dudek S.M., Camp S.M., Chiang E.T., Singleton P.A., Usatyuk P.V., Zhao Y., et al. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor. Cell Signal 2007, 19:1754-1764.
20. Siehler S., Manning D.R. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim Biophys Acta 2002, 1582:94-99.
21. Sammani S., Moreno-Vinasco L., Mirzapoiazova T., Singleton P.A., Chiang E.T., Evenoski C.L., et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol 2010, 43:394-402.
22. Kovarik J.M., Schmouder R., Barilla D., Riviere G.J., Wang Y., Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004, 44:532-537.
23. Kovarik J.M., Schmouder R.L., Serra D., Wang Y., Wiegand H., Dilzer S.C., et al. FTY720 p.armacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 2005, 45:446-452.
24. Kovarik J.M., Schmouder R.L., Hartmann S., Riviere G.J., Picard F., Voss B., et al. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 2006, 46:149-156.
25. Kovarik J.M., Dole K., Riviere G.J., Pommier F., Maton S., Jin Y., et al. Ketoconazole increases fingolimod blood levels in a drug Interaction via CYP4F2 inhibition. J Clin Pharmacol 2008, 49:212-218.
26. Hocke A.C., Temmesfeld-Wollbrueck B., Schmeck B., Berger K., Frisch E.M., Witzenrath M., et al. Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: inhibition of endothelial gap formation by adrenomedullin. Histochem Cell Biol 2006, 126:305-316.
27. Hocke A.C., Hartmann I.K., Eitel J., Optiz B., Scharf S., Suttorp N., et al. Subcellular expression pattern and role of IL-15 in pneumococci induced lung epithelial apoptosis. Histochem Cell Biol 2008, 130:165-176.
28. Muller H.C., Witzenrath M., Tschernig T., Gutbier B., Hippenstiel S., Santel A., et al. Adrenomedullin attenuates ventilator-induced lung injury in mice. Thorax 2010, 65:1077-1084.
29. Muller H.C., Hellwig K., Rosseau S., Tschernig T., Schmiedl A., Gutbier B., et al. Simvastatin attenuates ventilator-induced lung injury in mice. Crit Care 2010, 14:R143.
30. Sanchez T., Estrada-Hernandez T., Paik J.H., Wu M.T., Venkataraman K., Brinkmann V., et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell Growth factor-induced vascular permeability. J Biol Chem 2003, 278:47281-47290.
31. Camp S.M., Bittman R., Chiang E.T., Moreno-Vinasco L., Mirzapoiazova T., Sammani S., et al. Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther 2009, 331:54-64.
32. Sanchez T., Skoura A., Wu M.T., Casserly B., Harrington E.O., Hla T. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol 2007, 27:1312-1318.
33. Brinkmann V., Davis M.D., Heise C.E., Albert R., Cottens S., Hof R., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002, 277:21453-21457.
34. Bohler T., Guillebaud J., Etienne L., Canivet C., Kamar N., Rostaing L., et al. Effect of FTY720 on apoptosis of smooth muscle cells. Transplant Proc 2007, 39:2624-2626.
35. Hung J.H., Lu Y.S., Wang Y.C., Ma Y.H., Wang D.S., Kulp S.K., et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res 2008, 68:1204-1212.
36. Puneet P., Yap C.T., Wong L., Lam Y., Koh D.R., Moochhala S., et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 2010, 328:1290-1294.
37. Daniel C., Sartory N., Zahn N., Geisslinger G., Radeke H.H., Stein J.M. FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 2007, 178:2458-2468.
38. Galvao V.R., Ginoza M., Franco M., Burdmann E.A., Bueno V. Prolonged administration of FTY720 does not cause renal toxicity in mice. Transplant Proc 2005, 37:112-113.
39. Kaudel C.P., Frink M., van Griensven M., Schmiddem U., Probst C., Bergmann S., et al. FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model. Transplant Proc 2007, 39:493-498.
40. Esteban A., Anzueto A., Frutos F., Alia I., Brochard L., Stewart T.E., et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002, 287:345-355.
41. Bhandari V., Choo-Wing R., Lee C.G., Zhu Z., Nedrelow J.H., Chupp G.L., et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006, 12:1286-1293.
42. Verbrugge S.J., Lachmann B., Kesecioglu J. Lung protective ventilatory strategies in acute lung injury and acute respiratory distress syndrome: from experimental findings to clinical application. Clin Physiol Funct Imaging 2007, 27:67-90.
43. Sun W.Y., Pitson S.M., Bonder C.S. Tumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial {alpha}5{beta}1 integrin. Am J Pathol 2010, 177:436-446.
44. Hammerschmidt S., Kuhn H., Grasenack T., Gessner C., Wirtz H. Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar type II cells. Am J Respir Cell Mol Biol 2004, 30:396-402.
45. Gattinoni L., Pesenti A. The concept of "baby lung". Intensive Care Med 2005, 31:776-784.